Abstract
QT dispersion has been reported to increase in patients with essential hypertension, and abnormal QT dispersion is associated with arrythmias and sudden cardiac death. However, whether change in QT dispersion is related to oxidative stress is unclear. We examined the effect of the angiotensin II receptor blocker valsartan on QT dispersion and the relationship between oxidative stress and QT dispersion in patients with essential hypertension. Hypertensive patients whose systolic blood pressure (SBP) was more than 140 mmHg and/or diastolic blood pressure (DBP) was more than 90 mmHg were treated with valsartan. Blood pressure was measured once a month for 6 months. The difference between the maximal and minimal QT intervals within a 12-lead surface ECG was measured and QT dispersion and QTc dispersion corrected by heart rate were obtained before and 6 months after treatment. Left ventricular mass (LVM) assessed by echocardiography was obtained at baseline and 6 months after treatment. Venous blood samples were obtained at baseline and 6 months after treatment to measure serum levels of lipoperoxidation (LPO) and type I and III procollagen. Treatment with valsartan significantly decreased SBP and DBP. QTc dispersion decreased significantly 6 months after treatment with valsartan as compared to the baseline values. Valsartan treatment did not affect the LVM. Valsartan significantly decreased the abnormally high LPO levels. The changes in QTc dispersion were positively correlated with changes in the serum levels of LPO and with changes in DBP. The correlation between changes in LPO and QTc dispersion was more close than that between changes in DBP and QTc dispersion. In conclusion, antihypertensive therapy with valsartan reduces QTc dispersion and this may be related to the ability of valsartan to reduce oxidative stress in patients with essential hypertension.
Similar content being viewed by others
Article PDF
References
Levy D, Garrison RJ, Savage DD, Kannel EB, Castelli WP : Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–1566.
Kannel WB : Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens Suppl 1991; 9 ( 2): S3–S9.
Messerli FH, Schmieder R : Left ventricular hypertrophy. A cardiovascular risk factor in essential hypertension. Drugs 1986; 31 ( Suppl 4): 192–201.
Frohlich ED : Fibrosis and ischemia: the real risks in hypertensive heart disease. Am J Hypertension 2001; 14: 194S–199S.
van de Loo A, Arendts W, Hohnloser SH : Variability of QT dispersion measurements in the surface electrocardiogram in patients with acute myocardial infarction and in normal subjects. Am J Cardiol 1994; 74: 1113–1118.
Zabel M, Portnoy S, Franz MR : Electrocardiographic indexes of dipersion of ventricular repolarization: an isolated heart validation study. J Am Coll Cardiol 1995; 25: 746–754.
Barr CS, Naas A, Freeman M, Lang CC, Struthers AD : QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994; 343: 327–329.
Zareba W, Moss AJ, Lecessie S : Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease. Am J Cardiol 1994; 74: 550–553.
de Bruyne MC, Hoes AW, Kors JA, Hofman A, Van Bemmel JH, Grobbee DE : QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation 1998; 97: 467–472.
Davey PP, Bateman J, Mulligan IP, Forfar C, Barlow C, Hart G : QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities. Heart 1994; 71: 268–273.
Clarkson PBM, Naas AAO, McMahon A, MacLeod C, Hart G : QT interval dispersion in essential hypertension. QJM 1995; 88: 327–332.
Matsumura K, Takata Y, Ansai T, et al: Association of QT interval with blood pressure in 80-year-old subjects. Hypertens Res 2004; 27: 387–391.
Grozier IG, Richards AM, Ikram H, Nicholls MG : The renin-angiotensin system, ACE inhibitors, and cardiac structure, in Robertson JIS ( ed): The Renin-Angiotensin System. New York, Gower Medical Publishing, 1993, pp 1–94.
Weber KT, Brilla CG : Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849–1865.
Bednarz B, Chamiec T, Ceremuzynski L : Antioxidant vitamins decrease exercise-induced QT dispersion after myocardial infarction. Kardiol Pol 2003; 58: 375–379.
Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 7: 450–458.
Dahlof B, Pennart K, Hansson L : Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95–110.
Mylona-Karayanni C, Gourgiotis D, Bossios A, Kamper EF : Oxidative stress and adhesion molecules in children with type 1 diabetes mellitus: a possible link. Pediatr Diabetes 2006; 7: 51–59.
Kawano H, Toda G, Nakamizo R, Koide Y, Seto S, Yano K : Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J 2005; 69: 1244–1248.
Poulsen SH, Andersen NH, Heickendorff L, Mogensen CE : Relation between plasma amino-terminal propeptide of procollagen type III and left ventricular longitudinal strain in essential hypertension. Heart 2005; 91: 624–629.
Jeron A, Hengstenberg C, Engel S, et al: The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction. Eur Heart J 2001; 22: 618–621.
Gonzalez-Juanatey JR, Garcia-Acuna JM, Pose A, et al: Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril. Am J Cardiol 1998; 81: 170–174.
Ranade V, Molnar J, Khokher T, Agarwal A, Mosnaim A, Somberg JC : Effect of angiotensn-converting enzyme therapy on QT interval dispersion. Am J Ther 1999; 6: 257–261.
Lim PO, Nys M, Naas AAO, Struthers AD, Osbakken M, MacDonald TM : Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension 1999; 33: 713–718.
Malmqvist K, Kahan T, Edner M, Bergfeldt L : Comparison of action of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Am J Cardiol 2002; 90: 1107–1112.
Crozier IG, Richards AM, Ikram H, Nicholls MG : The renin-angiotensin system, ACE inhibitors, and cardiac structure, in Robertson JIS ( ed): The Renin-Angiotensin System. New York, Gower Medical Publishing, 1993, pp 1–94.
Weber KT, Brilla CG : Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849–1865.
Karpanou EA, Vyssoulis GP, Psichogios A, et al: Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J 1998; 136: 765–768.
Ohta M, Nanri H, Matsushima Y, Sato Y, Ikeda M : Blood pressure–lowering effects of lifestyle modification: possible involvement of nitric oxide bioavailability. Hypertens Res 2005; 28: 779–786.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miyajima, K., Minatoguchi, S., Ito, Y. et al. Reduction of QTc Dispersion by the Angiotensin II Receptor Blocker Valsartan May Be Related to Its Anti-Oxidative Stress Effect in Patients with Essential Hypertension. Hypertens Res 30, 307–313 (2007). https://doi.org/10.1291/hypres.30.307
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.307
Keywords
This article is cited by
-
Molecular Studies on Coronary Artery Disease—A Review
Indian Journal of Clinical Biochemistry (2013)